The global Angina Pectoris drugs market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 3% during the forecast period (2022-2029).
Angina pectoris, or angina for short, refers to chest pain or discomfort caused by the insufficient blood supply to the heart muscle, known as myocardial ischemia when myocardial oxygen demand exceeds oxygen supply. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74.
The global angina pectoris drugs market growth is driven by the increasing burden of lifestyle diseases that directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment.
The high incidence rate of angina pectoris is expected to drive the growth in the forecast period
The market is primarily driven by the high incidence rate of angina pectoris across the globe. According to an article published in the British Journal of Cardiology, around 2%-4% of the population in Western countries is affected with chronic stable angina pectoris. An article published in Medscape states that more than 9.8 million people in America experience the symptoms of angina annually and more than 500,000 cases are registered every year. Easy availability of therapeutic drugs for angina pectoris, new product launches, and rise in awareness regarding various cardiological disorders in the developed countries are projected to fuel the growth of the global angina pectoris therapeutics market during the forecast period.
Increase burden of lifestyle diseases is expected to drive the market growth
Lifestyle diseases and their chronic nature is among the pivotal reason for the high cardiovascular-related disorders globally. As per the Nesia Foundation Hospital, globally, about 14.2 million people between the age group 30-69 years, die prematurely from lifestyle disorders such as diabetes, arteriosclerosis, high cholesterol, stroke, nephritis, cancer, and several others. As per several published data on lifestyle-related diseases, women have more atypical signs of heart attack more often than men. In addition, in several cases, there is increased misdiagnosis or delayed diagnosis which eliminate the likeliness to receive immediate life-saving treatment of primary angioplasty and stents. The increasing burden of lifestyle diseases directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment. Thus, the increasing burden of lifestyle diseases majorly drives the demand and need for the angina pectoris drugs market.
Regulatory obstruction is likely to hinder the market growth
However, the high cost of the treatment and stringent government regulations and policies related to drug patents may restrict the growth of the market growth in the forecast period.
COVID-19 Impact Analysis
The pain was a characteristic symptom of the patients presented, while some of them expressed chest pain mimicking angina pectoris. Patients with angina pectoris diseases are extremely vulnerable to the attacks of the new virus. In particular, those with ischemic heart diseases and heart failure (HF), when infected, present high morbidity and mortality. The aforementioned risks are increased when elderly patients with diabetes mellitus are concerned. For this reason, the worldwide recommendation for these patients is to remain in prolonged lockdown and quarantine if they come in contact with people infected by COVID-19. Thus this factor is driving the growth of the market in the forecast period.
The beta-blockers segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Beta-blockers work by blocking the effect of adrenaline on the heart by providing benefits such as Slowing the heart rate and reducing the force of heart muscle contraction. In patients with stable angina caused by CAD, beta-blockers are considered first-line therapy. Beta-Blockers has the smallest share in the market as the majority of beta-blocker drugs are predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. They are prescribed for several different conditions including high blood pressure, angina, some abnormal heart rhythms, heart, anxiety, migraine, glaucoma, and overactive thyroid symptoms. Beta-blockers also obstruct the production of angiotensin II, a hormone produced by the kidneys. Reducing the amount of angiotensin relaxes and widens the blood vessels, easing the flow of blood through the vessels. When these receptors are stimulated, they cause various effects. For instance, nerve impulses to the heart can stimulate beta-adrenergic receptors on heart cells. This causes an increase in the force and rate of the heartbeat.
Calcium Channel Blockers has the second-largest share in the market. Calcium channel blockers lower your blood pressure by preventing calcium from entering the cells of your heart and arteries. Calcium causes the heart and arteries to contract more strongly. By blocking calcium, calcium channel blockers allow blood vessels to relax and open. Some calcium channel blockers have the added benefit of slowing the heart rate, which can further lower blood pressure, relieve chest pain (angina) and control an irregular heartbeat.
The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker segment growth. Hypertension often referred to as elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of death and around 17.9 million people died in 2016 due to it. Calcium antagonists are known to be effective against this indication. These factors are driving the growth of the segment in the forecast period.
The hospital pharmacy is expected to dominate the angina pectoris drugs market during the forecast period
The hospital pharmacies held the largest share in the angina pectoris drugs market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global Angina Pectoris drugs market
North America region is dominating the global Angina Pectoris drugs market accounted for the largest market share in 2020. The rising adoption of therapeutics and the presence of key manufacturers in the U.S is responsible for its large share. Ischemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, the increasing incidence of cardiac disorders due to the sedentary lifestyle and favourable regulatory initiatives are fueling the market growth.
The angina pectoris drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Orion Corporation, Merck & Co. Inc., and Cardiorentis AG., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the angina pectoris drugs market globally.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centres, hospitals, and pharmacies.
Product Portfolio: The Company’s portfolio is comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
Get your free sample proposal with a single click!